DE69924232D1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number
DE69924232D1
DE69924232D1 DE69924232T DE69924232T DE69924232D1 DE 69924232 D1 DE69924232 D1 DE 69924232D1 DE 69924232 T DE69924232 T DE 69924232T DE 69924232 T DE69924232 T DE 69924232T DE 69924232 D1 DE69924232 D1 DE 69924232D1
Authority
DE
Germany
Prior art keywords
insulin preparations
stabilized insulin
glycylglycine
analogue
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924232T
Other languages
English (en)
Inventor
Peter Langballe
Elsebeth Norup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69924232D1 publication Critical patent/DE69924232D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DE69924232T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen Expired - Lifetime DE69924232D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98610001 1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en) 1998-01-09 1999-01-06 Stabilised insulin compositions

Publications (1)

Publication Number Publication Date
DE69924232D1 true DE69924232D1 (de) 2005-04-21

Family

ID=8235844

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924232T Expired - Lifetime DE69924232D1 (de) 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen

Country Status (7)

Country Link
US (1) US6174856B1 (de)
EP (1) EP1044016B1 (de)
JP (1) JP2002500196A (de)
AT (1) ATE290877T1 (de)
AU (1) AU1870099A (de)
DE (1) DE69924232D1 (de)
WO (1) WO1999034821A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
EP1146896B1 (de) * 1999-01-26 2002-07-24 Eli Lilly And Company Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
AU2001284364B2 (en) * 2000-07-31 2006-09-28 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) * 2001-12-04 2003-08-21 Philip Hougaard Method of planning and performing stability studies
WO2003075950A1 (en) * 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094951A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) * 2002-12-31 2004-07-01 Medtronic Minimed, Inc. Functionalization of immobilized proteins
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
JP5220410B2 (ja) 2004-07-19 2013-06-26 バイオコン・リミテッド インスリン−オリゴマー複合体、その処方物及び使用
EP1817049B1 (de) 2004-11-22 2012-08-01 Novo Nordisk A/S Lösliche, stabile insulinhaltige formulierungen mit einem protaminsalz
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
US8367606B2 (en) 2005-08-29 2013-02-05 Healor Ltd. Method and compositions for prevention and treatment of diabetic and aged skin
PT1969004E (pt) * 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
ES2387955T3 (es) * 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
EP2024390B1 (de) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulinderivate
BRPI0712041A2 (pt) * 2006-05-09 2011-12-27 Novo Nordisk As derivado de insulina
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101835486B (zh) * 2007-07-30 2012-12-12 希尔洛有限公司 用于治疗创伤的药物组合物以及相关方法
RU2453332C2 (ru) * 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
ES2613152T3 (es) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
EP2113564A1 (de) * 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) * 2008-06-24 2012-11-16 Arjowiggins Licensing Sas Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
LT3228320T (lt) 2008-10-17 2020-03-10 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2391218B1 (de) 2009-01-28 2020-03-18 Smartcells, Inc. Konjugatbasierte systeme für kontrollierte wirkstofffreisetzung
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
DK2451437T3 (en) * 2009-07-06 2017-02-13 Sanofi Aventis Deutschland Aqueous INSULIN PREPARATIONS CONTAINING METHIONIN
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
NZ599848A (en) 2009-11-13 2013-08-30 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
EP2599494A1 (de) 2010-01-11 2013-06-05 Healor Ltd. PKC-Inhibitoren zur Behandlung von entzündlichen Erkrankungen
WO2012006283A1 (en) * 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
BR112015011179A8 (pt) 2012-12-19 2019-10-01 Wockhardt Ltd composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
WO2016137569A1 (en) * 2015-02-25 2016-09-01 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
ES2912162T3 (es) 2017-06-01 2022-05-24 Lilly Co Eli Composiciones de insulina de acción rápida
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
PE20230457A1 (es) 2020-03-31 2023-03-10 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
JP2628340B2 (ja) * 1988-05-14 1997-07-09 株式会社いかがく 血液中のインシュリン成分の安定方法
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE69416409T2 (de) * 1993-06-21 1999-09-16 Novo Nordisk As Asp-b28-insulinkristalle
ES2163451T3 (es) * 1993-09-17 2002-02-01 Novo Nordisk As Insulina acilada.
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
EP0921812B2 (de) * 1996-06-20 2011-12-21 Novo Nordisk A/S Halogenid-enthaltende insulinzubereitungen

Also Published As

Publication number Publication date
ATE290877T1 (de) 2005-04-15
WO1999034821A1 (en) 1999-07-15
EP1044016B1 (de) 2005-03-16
AU1870099A (en) 1999-07-26
JP2002500196A (ja) 2002-01-08
EP1044016A1 (de) 2000-10-18
US6174856B1 (en) 2001-01-16

Similar Documents

Publication Publication Date Title
DE69924232D1 (de) Stabilisierte insulin-zubereitungen
NO20015088D0 (no) Desinfiserende sammensetning basert på H2O2, syrer og metallioner
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
HU9902655D0 (en) Pharmaceutical composition of hedgehog proteins and use thereof
IL127366A0 (en) Insulin preparations containing NaCl
NO20012994D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
NO20015471D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
NO20031860L (no) Kahalalid F
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
RS50355B (sr) Formulacije eritropoietina sa više doza
MY138219A (en) Biologically active peptides
GB2349150B (en) Expression of DNA or proteins in C. Elegans
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
DE69813833D1 (de) 4-cyano-4-deformylsordarizin-derivate
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
DE69815355D1 (de) 4-cyano-4-deformylsordarinderivate
SE9502927D0 (sv) Solution containing IGF-I
DE69602208T2 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine
Kleinjohann Erratum to: Architecture and Design of Distributed Embedded Systems
ES2178911A1 (es) Peptidos bioactivos derivados de las transferrinas.

Legal Events

Date Code Title Description
8332 No legal effect for de